Калкулатор за CJC-1295 (без DAC)

CJC-1295 No DAC – The Complete Guide

CJC-1295 No DAC (without Drug Affinity Complex) is a synthetic analog of endogenous Growth Hormone-Releasing Hormone (GHRH). By binding to pituitary GHRH receptors, it stimulates natural, pulsatile growth hormone secretion. This guide covers everything you need to know: mechanism of action, dosing, reconstitution, storage, side effects, and how to combine it effectively with peptides like Ipamorelin.

Medical Disclaimer: The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Peptides are not approved drugs for human use. Always consult a qualified healthcare provider before using peptides.

1. What Is CJC-1295 No DAC?

CJC-1295 No DAC — also called Modified GRF(1-29) or Mod GRF 1-29 — is a 29-amino-acid peptide derived from the first 29 residues of native GHRH. Four strategic amino acid substitutions (at positions 2, 8, 15, and 27) protect it from dipeptidyl peptidase IV (DPP-IV) enzymatic cleavage, increasing stability and receptor binding affinity compared to native GHRH while preserving the short, pulsatile pattern of GH release.

The key distinction from CJC-1295 with DAC is the absence of the Drug Affinity Complex. Without DAC, the peptide cannot covalently bind albumin in the bloodstream, resulting in a half-life of approximately 30 minutes rather than 6–8 days. This shorter half-life produces discrete GH pulses that more closely mirror the body's natural ultradian rhythm — a property many researchers consider more physiologically appropriate.

Mechanism of Action

CJC-1295 No DAC binds to the GHRH receptor on somatotroph cells in the anterior pituitary. Receptor activation triggers intracellular cAMP signaling, leading to GH synthesis and release. The released GH then stimulates hepatic production of IGF-1 (Insulin-like Growth Factor 1), which mediates many of the downstream anabolic and lipolytic effects.

Potential effects mediated by increased GH and IGF-1 include:

• Increased lean muscle mass and protein synthesis
• Enhanced fat oxidation and improved body composition
• Accelerated recovery from exercise and injury
• Improved sleep quality, particularly deep (slow-wave) sleep
• Support for bone density and connective tissue health
• Potential anti-aging effects on skin, collagen, and cellular repair

2. Dosage Calculation

Accurate dosage calculation is critical for both efficacy and safety. The standard dosing parameters for CJC-1295 No DAC are:

• Per injection dose: 100–200 mcg (0.1–0.2 mg)
• Frequency: 1–3 times per day
• Typical daily total: 200–600 mcg

Example Calculation: 10 mg Vial

The standard BergdorfBio vial contains 10 mg of lyophilized CJC-1295 No DAC. Adding 2 ml of bacteriostatic water (BAC water) gives a concentration of:

10 mg ÷ 2 ml = 5 mg/ml = 5,000 mcg/ml

Using a standard U100 insulin syringe (100 units = 1 ml):

• 100 mcg = 0.02 ml = 2 units
• 150 mcg = 0.03 ml = 3 units
• 200 mcg = 0.04 ml = 4 units

At 200 mcg twice daily, one 10 mg vial lasts 25 days. At 100 mcg once daily, the same vial lasts 100 days.

Use Our Peptide Calculator

For precise volume calculations based on your vial size, reconstitution volume, and target dose, use the BergdorfBio Peptide Calculator. Enter your vial parameters and desired dose to get the exact volume to draw.

3. Dosing Protocol

Beginner Protocol (100 mcg / once daily)

Start with a single 100 mcg injection in the evening, 30–60 minutes before sleep, on an empty stomach. This approach takes advantage of the natural nocturnal GH pulse and allows you to assess individual tolerance over the first 1–2 weeks before increasing frequency or dose.

Standard Protocol (100–200 mcg / twice daily)

The most widely used protocol consists of two daily injections:

• Injection 1: Morning, fasted (at least 2 hours after any meal or before breakfast)
• Injection 2: Evening, 30–60 minutes before bed, fasted

Insulin strongly suppresses GH release, so timing injections away from meals — especially carbohydrate-rich meals — is essential. For those combining with Ipamorelin, both peptides can be drawn into the same syringe and injected together.

Advanced Protocol (200 mcg / three times daily)

Experienced users may add a third injection at midday, fasted or at least 2 hours post-meal. Three daily injections provide more sustained IGF-1 elevation throughout the day but require stricter meal timing discipline.

Cycle Recommendations

Typical cycles run 8–12 weeks followed by a 4-week break. Some users report sustained benefits with longer 3–6 month cycles, though long-term human data remains limited. Cycle breaks help prevent desensitization of pituitary GHRH receptors.

4. Reconstitution

CJC-1295 No DAC is supplied as a lyophilized (freeze-dried) powder and must be reconstituted before injection. You will need:

• Bacteriostatic water (BAC water) — preferred for multi-dose vials
• Sterile alcohol swabs
• A draw needle (18–21 gauge) for transferring BAC water
• U100 insulin syringes for injection

Step-by-Step Reconstitution

1. Wipe the rubber septa of both vials with fresh alcohol swabs. Allow to air-dry.
2. Draw 2 ml of BAC water into the transfer syringe.
3. Insert the needle into the peptide vial at an angle, with the tip touching the glass wall — not the powder directly.
4. Release the BAC water slowly so it runs down the inside of the glass. Never inject directly onto the lyophilized cake.
5. Gently swirl (do not shake) the vial until all powder is fully dissolved.
6. The resulting solution should be clear and colorless. Discard if cloudy, colored, or if visible particles are present.

Use only bacteriostatic water or sterile water for injection. Do not use tap water, distilled water from consumer bottles, or saline solution not intended for injection.

5. Storage

• Before reconstitution: Store at 2–8 °C (refrigerated) or at room temperature below 25 °C for short periods. Protect from light and heat.
• After reconstitution: Always refrigerate at 2–8 °C. Reconstituted solution remains stable for up to 30 days.
• Do not freeze reconstituted peptide — freezing degrades the protein structure and renders it ineffective.
• Wipe the rubber septum with a fresh alcohol swab before each draw to maintain sterility.
• Never store vials in direct sunlight or in areas subject to temperature fluctuations above 30 °C.

6. Side Effects

CJC-1295 No DAC has a well-established tolerability profile when used at recommended doses. Known and potential side effects include:

Common Side Effects

• Water retention: Mild edema, particularly in the hands and feet, is the most commonly reported effect. Usually dose-dependent and temporary, resolving within the first few weeks as the body adapts.
• Tingling or numbness: Paresthesia in the hands or fingers, resembling carpal tunnel sensations. Generally transient.
• Injection site reactions: Minor redness, swelling, or itching at the injection site. Rotate injection sites to minimize localized irritation.
• Fatigue or drowsiness: Particularly after evening injections; this effect can be beneficial for sleep quality.
• Headache: Occasionally reported at the start of a cycle.

Less Common Side Effects

• Flushing (transient warmth or redness in the face)
• Nausea, particularly if the injection is administered too rapidly
• Dizziness

When to Discontinue Use

Discontinue immediately and consult a physician if you experience persistent swelling, severe headache, visual disturbances, joint pain, or any other concerning symptoms. CJC-1295 No DAC is contraindicated in individuals with active malignancies, pituitary disorders, insulin resistance/diabetes (without medical supervision), or pregnancy.

7. Combinations

CJC-1295 No DAC + Ipamorelin — The Classic Stack

The combination of CJC-1295 No DAC with Ipamorelin is the most widely studied and used GHRH/GHRP protocol. The synergy arises from complementary mechanisms: CJC-1295 activates the GHRH receptor, while Ipamorelin activates the ghrelin receptor (GHS-R1a). Simultaneous activation of both pathways produces a substantially larger GH pulse than either peptide alone.

Ipamorelin is particularly valued in this stack because it does not significantly raise cortisol or prolactin levels — a key advantage over older GHRPs like GHRP-2 or GHRP-6. The two peptides are fully compatible and can be mixed in the same syringe.

Recommended Stack Protocol

• 100–200 mcg CJC-1295 No DAC + 200–300 mcg Ipamorelin per injection
• 2x daily: morning (fasted) and evening (30–60 min before sleep)
• Can be combined in one syringe; inject subcutaneously

CJC-1295 No DAC + AOD-9604

For individuals primarily targeting fat loss and body recomposition, AOD-9604 (a lipolytic GH fragment) can be added. AOD-9604 acts directly on adipocytes to promote fat breakdown without stimulating systemic GH or IGF-1 levels, making the combination complementary rather than redundant.

8. FAQ

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC contains a Drug Affinity Complex that enables covalent albumin binding, extending its half-life to 6–8 days. This allows for once-weekly injections but produces a sustained, blunted GH elevation rather than discrete pulses. CJC-1295 No DAC has a ~30-minute half-life and produces more physiological, pulsatile GH release. Most research protocols and practitioners favor the No DAC version for its more natural GH profile.

Can CJC-1295 No DAC and Ipamorelin be mixed in the same syringe?

Yes. Both peptides are chemically compatible. Draw one peptide into the insulin syringe first, then add the second. Inject subcutaneously immediately after mixing. Do not store pre-mixed peptides.

What is the best time to inject CJC-1295 No DAC?

The two most effective windows are: (1) morning, immediately upon waking before any food or carbohydrate intake; and (2) approximately 30–60 minutes before sleep. Both windows coincide with naturally low insulin levels, which maximize pituitary GH responsiveness. Avoid injecting within 2 hours of a carbohydrate-heavy meal.

How long before results are noticeable?

Most users notice improved sleep quality and faster exercise recovery within 3–4 weeks. Observable changes in body composition — increased muscle definition, reduced subcutaneous fat — typically emerge after 8–12 weeks. This timeline reflects the gradual rise and sustained elevation of IGF-1 required for tissue-level changes.

Does CJC-1295 No DAC suppress natural GH production?

Unlike synthetic GH administration, CJC-1295 No DAC works by amplifying the pituitary's existing capacity to produce and release GH — it does not introduce exogenous GH. Most research suggests that properly cycled GHRH analogs do not suppress the hypothalamic-pituitary axis, though prolonged continuous use theoretically risks receptor desensitization. Cycling is recommended as a precaution.

Do I need blood work before starting?

It is strongly recommended to establish baseline IGF-1 levels and rule out contraindications before starting any GHRH analog. A physician can also monitor IGF-1 during a cycle to ensure levels remain in a safe, physiological range. Elevated IGF-1 beyond normal ranges is associated with adverse health risks.

Where can I buy CJC-1295 No DAC?

BergdorfBio offers research-grade CJC-1295 No DAC with verified purity. Each vial is tested for identity and concentration. Visit the CJC-1295 No DAC product page for current availability and pricing.

Is CJC-1295 No DAC legal?

The legal status of CJC-1295 No DAC varies by jurisdiction. In most countries it is not approved for human pharmaceutical use and is classified as a research chemical. It is prohibited in competitive sports under WADA regulations. Always verify the regulations applicable in your country before purchasing or using this peptide.

Related Peptides

• Ipamorelin — Selective GHRP for the classic CJC-1295 stack
• AOD-9604 — GH fragment peptide for targeted fat loss

Disclaimer: This content is for informational and research purposes only. CJC-1295 No DAC is not an approved drug for human therapeutic use. The applications described have not been evaluated or approved by the FDA, EMA, or any other regulatory authority. Do not use peptides without the supervision of a qualified medical professional.